Brent Sharpe, MD
Urology · Gainesville, GANPI 1821041476
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $26,936 of the $36,724 with a category attached, or 73.3%. Angiodynamics, Inc. accounts for 73.5% of it on its own, with 35 other manufacturers making up the rest. 2025 is the largest year on record at $29,981, more than ten times the $901 reported in 2019. Among urology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 244 payments — averaging $150.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$27K
- Boston Scientific$3K
- Procept Biorobotics Corporation$3K
- Sumitomo Pharma America, Inc.$424
- Bayer$322
- Neotract Inc.$296
- plus $2K from 30 others
What the payments were for
- Consulting fees$26,93673%
- Speaking & faculty fees$2,6007%
- Travel & lodging$1,6565%
- Food & beverage$5,46815%
- Education$640%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 47 | $26,984 |
| Boston Scientific | 42 | $3,179 |
| Procept Biorobotics Corporation | 11 | $3,123 |
| Sumitomo Pharma America, Inc. | 18 | $424 |
| Bayer | 11 | $322 |
| Neotract Inc. | 5 | $296 |
| Olympus America Inc. | 11 | $284 |
| Axonics, Inc. | 12 | $247 |
| Antares Pharma, Inc. | 14 | $247 |
| Teleflex LLC | 4 | $196 |
| Valencia Technologies Corporation | 1 | $139 |
| Coloplast | 8 | $124 |
| Pfizer | 4 | $99 |
| Endo Pharmaceuticals Inc. | 5 | $89 |
| Dendreon Pharmaceuticals LLC | 3 | $79 |
| Dentsply IH AB | 2 | $76 |
| Myriad Genetic Laboratories, Inc. | 3 | $69 |
| Laborie Medical Technologies Corp. | 4 | $67 |
| Tempus AI, Inc | 3 | $67 |
| Verity Pharmaceuticals Inc. | 3 | $64 |
| Astellas Pharma US Inc | 3 | $63 |
| Tolmar, Inc. | 3 | $61 |
| Blue Earth Diagnostics | 3 | $58 |
| Convatec Inc. | 1 | $50 |
| AbbVie(2 entities) | 2 | $43 |
| Travere Therapeutics, Inc. | 10 | $39 |
| Ambu Inc. | 2 | $37 |
| AstraZeneca | 1 | $35 |
| Urogen Pharma, Inc. | 1 | $30 |
| Tolmar Pharmaceuticals, Inc. | 1 | $27 |
| Steris Corporation | 1 | $24 |
| Progenics Pharmaceuticals, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Rochester Medical Corporation | 1 | $19 |
| EDAP Technomed Inc | 1 | $12 |
| Novo Nordisk | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$23,987
- AquaBeam Robotic System$2,949
- AlphaVac$2,500
- rezum Generator$2,250
- UroLift$255
- GreenLight XPS$146
- eCoin Device Kit$139
- UroLift System$126
- iTIND System$125
How this compares
$36,724 in reported general payments places this provider in the 95th percentile of 369 urology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 139 | $93,496 |
| MyrbetriqMirabegron | 69 | $48,856 |
| Tamsulosin Hcl | 273 | $2,849 |
| Doxycycline Monohydrate | 140 | $1,107 |
| Oxybutynin Chloride | 136 | $868 |
| Finasteride | 70 | $838 |
| Oxybutynin Chloride ErOxybutynin Chloride | 33 | $762 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 129 | $547 |
| Doxycycline Hyclate | 66 | $363 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $265 |
| Cefdinir | 27 | $259 |
| Methylprednisolone | 40 | $241 |
| Meloxicam | 56 | $215 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 13 | $116 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 22 | $93 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $424 | $93,496139 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $48,85669 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 369 urology providers in Georgia.
Other urology in Gainesville
- Vahan KassabianRoswell$1.6M
- Lewis KritemanRoswell$864K
- Daniel CanterDecatur$329K
- Tariq HakkyAtlanta$140K
- Sherita KingAugusta$108K
- Brittani Barrett-HarlowFayetteville$100K
- James BennettAtlanta$93K
- Anthony BarnesAtlanta$89K
- Scott MillerRoswell$85K
- Matthew SandAtlanta$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.